Do you feel comfortable using ribociclib in a patient with metastatic ER+/HER2+ breast cancer who has borderline systolic heart failure from previous HER2 based treatment?
Are you more worried about QT prolongation in this subset of patients?
Answer from: Medical Oncologist at Community Practice
My short answer to the question is, yes, I would feel comfortable treating a metastatic breast cancer with ribociclib despite the presence of borderline CHF related to prior anti-HER-2 therapy.
As always, in the treatment of metastatic breast cancer, decisions regarding treatment typically come dow...
Sign in or Register to read more